Search

Your search keyword '"Hawk, Ernest"' showing total 826 results
Start Over Author "Hawk, Ernest"
826 results on '"Hawk, Ernest"'

1. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.

Author

Hassan, Manal, Li, Donghui, Han, Younghun, Byun, Jinyoung, Hatia, Rikita, Long, Erping, Choi, Jiyeon, Kelley, Robin, Cleary, Sean, Lok, Anna, Bracci, Paige, Permuth, Jennifer, Bucur, Roxana, Yuan, Jian-Min, Singal, Amit, Jalal, Prasun, Ghobrial, R, Santella, Regina, Kono, Yuko, Shah, Dimpy, Nguyen, Mindie, Liu, Geoffrey, Parikh, Neehar, Kim, Richard, Wu, Hui-Chen, El-Serag, Hashem, Chang, Ping, Li, Yanan, Chun, Yun, Lee, Sunyoung, Gu, Jian, Hawk, Ernest, Sun, Ryan, Huff, Chad, Rashid, Asif, Amin, Hesham, Beretta, Laura, Wolff, Robert, Antwi, Samuel, Patt, Yehuda, Hwang, Lu-Yu, Klein, Alison, Zhang, Karen, Schmidt, Mikayla, White, Donna, Goss, John, Khaderi, Saira, Marrero, Jorge, Cigarroa, Francisco, Shah, Pankil, Kaseb, Ahmed, Roberts, Lewis, and Amos, Christopher

Subjects
Humans, Genome-Wide Association Study, Liver Neoplasms, Genetic Predisposition to Disease, Carcinoma, Hepatocellular, Male, Female, Middle Aged, North America, Case-Control Studies, Polymorphism, Single Nucleotide, Aged, Genetic Loci, White People
Abstract

BACKGROUND AND AIMS: Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been studied systematically by genome-wide approaches in large numbers of individuals from European descent populations (EDP). APPROACH AND RESULTS: We conducted a 2-stage genome-wide association study (GWAS) on HCC not affected by HBV infections. A total of 1872 HCC cases and 2907 controls were included in the discovery stage, and 1200 HCC cases and 1832 controls in the validation. We analyzed the discovery and validation samples separately and then conducted a meta-analysis. All analyses were conducted in the presence and absence of HCV. The liability-scale heritability was 24.4% for overall HCC. Five regions with significant ORs (95% CI) were identified for nonviral HCC: 3p22.1, MOBP , rs9842969, (0.51, [0.40-0.65]); 5p15.33, TERT , rs2242652, (0.70, (0.62-0.79]); 19q13.11, TM6SF2 , rs58542926, (1.49, [1.29-1.72]); 19p13.11 MAU2 , rs58489806, (1.53, (1.33-1.75]); and 22q13.31, PNPLA3 , rs738409, (1.66, [1.51-1.83]). One region was identified for HCV-induced HCC: 6p21.31, human leukocyte antigen DQ beta 1, rs9275224, (0.79, [0.74-0.84]). A combination of homozygous variants of PNPLA3 and TERT showing a 6.5-fold higher risk for nonviral-related HCC compared to individuals lacking these genotypes. This observation suggests that gene-gene interactions may identify individuals at elevated risk for developing HCC. CONCLUSIONS: Our GWAS highlights novel genetic susceptibility of nonviral HCC among European descent populations from North America with substantial heritability. Selected genetic influences were observed for HCV-positive HCC. Our findings indicate the importance of genetic susceptibility to HCC development.

Published
2024

6. Addressing cervical cancer disparities in Texas: Expansion of a community-based prevention initiative for medically underserved populations

Author

Batman, Samantha H, Varon, Melissa L, Daheri, Maria, Ogburn, Tony, Rivas, Saul D, Guerra, Laura, Toscano, Paul A, Gasca, Monica, Campos, Lori, Foster, Savanah, Martin, Melissa, Yvette Williams-Brown, Marian, Poindexter, Yvette, Reininger, Belinda, Salcedo, Mila P, Milbourne, Andrea, Fellman, Bryan, Fernandez, Maria E, Baker, Ellen, Gowen, Rose, Fisher-Hoch, Susan, Rodriguez, Ana M, Milan, Jessica, Pippin, Monica, Hawk, Ernest, and Schmeler, Kathleen M

Published
2023
Full Text
View/download PDF

8. Contributors

Author

Abdi, Salahadin, primary, Afonso, Anoushka M., additional, Aloia, Thomas A., additional, Baldini, Gabriele, additional, Banchs, Jose, additional, Baptista-Hon, Daniel T., additional, Basen-Engquist, Karen, additional, Bello, Rosalind S., additional, Ben-Eliyahu, Shamgar, additional, Bergdahl, Celena Scheede, additional, Bhatnagar, Sushma, additional, Botdorf, Joshua, additional, Botha, Christelle, additional, Brown, David L., additional, Buggy, Donal J., additional, Burbury, Kate L., additional, Butler, Joseph, additional, Cahill, Ronan, additional, Carli, Franco, additional, Carton, Meghan, additional, Cata, Juan P., additional, Connolly, Cara, additional, Corrales, German, additional, Cortes, Jose, additional, Craven, Kimberly D., additional, Crommett, John Wilson, additional, Crosby, Kristin P., additional, Guzman, Luis Felipe Cuellar, additional, Dabo-Trubelja, Anahita, additional, Dang, Anh Quynh, additional, De Camilli, Alessandro R., additional, Desai, Madhavi D., additional, Dhesi, Jugdeep, additional, Doctor, Jeson R., additional, Downs, Jennifer S., additional, Dubowitz, Julia A., additional, Echeverry, German, additional, Enlund, Mats, additional, Ewing, Linette, additional, Finnerty, Dylan, additional, Domgue, Joël Fokom, additional, Frenzel, John, additional, Gallagher, Colleen M., additional, García-Ortega, Dorian Yarih, additional, Gerstman, Michelle, additional, Ghoshal, Arunangshu, additional, Gottumukkala, Vijaya N.R., additional, Grocott, Michael P.W., additional, Guerra-Londono, Carlos E., additional, Gupta, Sushan, additional, Gyorki, David E., additional, Hales, Tim G., additional, Hawk, Ernest, additional, Heriot, Alexander G., additional, Herman, Joseph M., additional, Hiller, Jonathan G., additional, Hubbard, Ruth E., additional, Ismail, Hilmy, additional, Itzep, Nelda, additional, Jasper, Emily, additional, Javed, Saba, additional, Jha, Bhawna, additional, Jhanji, Shaman, additional, Jones, Daryl, additional, Kapoor, Ravish, additional, Khan, Faraz, additional, Killinger, James S., additional, Koschel, Samantha, additional, Kotin, Alan, additional, Kulkarni, Atul Prabhakar, additional, La Caze, Adam, additional, Lawrentschuk, Nathan, additional, Leddy, Lauren Adrienne, additional, Ledet, Celia R., additional, Levett, Denny Z.H., additional, Leung, Debra, additional, Lin, Hui-Shan, additional, Lewis, Alexandra L., additional, Ma, Daqing, additional, Madden, Kevin, additional, Maitra, Anirban, additional, Maresso, Karen Colbert, additional, Mascarenhas, Jennifer, additional, McQueen, K. A. Kelly, additional, Mejia, Rodrigo, additional, Miles, Lachlan F., additional, Mohiuddin, Sana, additional, Molena, Daniela, additional, Moo, Tracy-Ann, additional, Moody, Karen, additional, Murphy, Declan G., additional, Myatra, Sheila Nainan, additional, Nates, Joseph L., additional, Nelson, Jonas A., additional, Eochagáin, Aisling Ní, additional, O’Connor, Ellen, additional, Okhuysen-Cawley, Regina, additional, Owusu-Agyemang, Pascal, additional, Pantvaidya, Gouri H., additional, Papadopoulos, Pamela C., additional, Parat, Marie-Odile, additional, Partridge, Judith, additional, Patel, Sephalie, additional, Patel, Vikram B., additional, Perry, Nicholas, additional, Polanco, Thais O., additional, Popovich, Shannon M., additional, Poulogiannis, George, additional, Rafael, Perez-Gonzalez Oscar, additional, Rampes, Sanketh, additional, Rao, Krithika S., additional, Raty, Sally Radelat, additional, Razvi, Shehla, additional, Reid, Natasha, additional, Ricon-Becker, Itay, additional, Riedel, Bernhard J., additional, Roarty, Emily B., additional, Rodriguez, Maria Alma, additional, Russo, Suzanne, additional, Saeed, Iqira, additional, Sahai, Sunil K., additional, Salins, Naveen, additional, Sathianathen, Niranjan, additional, Seth, Shveta, additional, Shaw, Paul N., additional, Sherwin, Aislinn, additional, Shete, Sanjay, additional, Shi, Qiuling, additional, Shields, Conor, additional, Tan, Jo-Lynn, additional, Tokita, Hanae K., additional, Wall, Tom, additional, Walters, Ronald S., additional, Wang, Xin Shelley, additional, Ward, Phil, additional, Waylen, Anna Louise, additional, Weinberg, Laurence, additional, Wichmann, Matthias Wilhelm, additional, Wigmore, Timothy, additional, Yusuf, Syed Wamique, additional, Zaky, Wafik, additional, and Zheng, Gang, additional

Published
2023
Full Text
View/download PDF

10. AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health

Author

Lippman, Scott M, Abate-Shen, Cory, Colbert Maresso, Karen L, Colditz, Graham A, Dannenberg, Andrew J, Davidson, Nancy E, Disis, Mary L, DuBois, Raymond N, Szabo, Eva, Giuliano, Anna R, Hait, William N, Lee, J Jack, Kensler, Thomas W, Kramer, Barnett S, Limburg, Paul, Maitra, Anirban, Martinez, Maria Elena, Rebbeck, Timothy R, Schmitz, Kathryn H, Vilar, Eduardo, and Hawk, Ernest T

Subjects
Genetics, Prevention, Cancer, Digestive Diseases, Human Genome, Good Health and Well Being, Biomedical Research, Congresses as Topic, Health Plan Implementation, Health Status Disparities, Humans, Neoplasms, Obesity, Primary Prevention, Public Health, Societies, Medical, Societies, Scientific, United States, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The recent pace, extent, and impact of paradigm-changing cancer prevention science has been remarkable. The American Association for Cancer Research (AACR) convened a 3-day summit, aligned with five research priorities: (i) Precancer Atlas (PCA). (ii) Cancer interception. (iii) Obesity-cancer linkage, a global epidemic of chronic low-grade inflammation. (iv) Implementation science. (v) Cancer disparities. Aligned with these priorities, AACR co-led the Lancet Commission to formally endorse and accelerate the NCI Cancer Moonshot program, facilitating new global collaborative efforts in cancer control. The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception. Microbiota-driven IL-17 can induce stemness and transformation in pancreatic precursors (identifying another repurposing opportunity). Notable progress also includes hosting an obesity special conference (connecting epidemiologic and molecular perspectives to inform cancer research and prevention strategies), co-leading concerted national implementation efforts in HPV vaccination, and charting the future elimination of cancer disparities by integrating new science tools, discoveries and perspectives into community-engaged research, including targeted counter attacks on e-cigarette ad exploitation of children, Hispanics and Blacks. Following this summit, two unprecedented funding initiatives were catalyzed to drive cancer prevention research: the NCI Cancer Moonshot (e.g., PCA and disparities); and the AACR-Stand Up To Cancer bold "Cancer Interception" initiative.

Published
2018

14. Building a Health Communication Brand for University of Texas System Tobacco Control

Author

Mackert, Michael, Case, Kathleen, Lazard, Allison, Oh, Jeeyun, Hughes Wagner, Jessica, Hawk, Ernest, Cofer, Jennifer, Hurst, Alex, Elerian, Nagla, and Lakey, David

Abstract

Objective: Despite declining cigarette smoking rates in the US, there is a continued need for tobacco prevention education campaigns to reach young adults. Recognizing the need for improved tobacco control messaging, the University of Texas (UT) System engaged The University of Texas at Austin Center for Health Communication to develop a brand and message that would strengthen tobacco control efforts at its 14 institutions. Methods: This article describes the iterative process involved in creating a brand for tobacco control, including an environmental scan, identifying potential message themes, and creating and refining logos. Results: This article highlights the process of developing a system-wide tobacco control brand. Specifically, the process included coordinating an interdisciplinary team with content and design experts, and presenting ideas to stakeholders for serial feedback and refinement, among others. Conclusions: Ultimately, this project offers a model for other systems of higher education interested in pursuing similar initiatives.

Published
2019
Full Text
View/download PDF

18. Supplementary Table S4 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome

Author

Deng, Nan, primary, Reyes-Uribe, Laura, primary, Fahrmann, Johannes F., primary, Thoman, Whittney S., primary, Munsell, Mark F., primary, Dennison, Jennifer B., primary, Murage, Eunice, primary, Wu, Ranran, primary, Hawk, Ernest T., primary, Thirumurthi, Selvi, primary, Lynch, Patrick M., primary, Dieli-Conwright, Christina M., primary, Lazar, Alexander J., primary, Jindal, Sonali, primary, Chu, Khoi, primary, Chelvanambi, Manoj, primary, Basen-Engquist, Karen, primary, Li, Yisheng, primary, Wargo, Jennifer A., primary, McAllister, Florencia, primary, Allison, James P., primary, Sharma, Padmanee, primary, Sinha, Krishna M., primary, Hanash, Samir, primary, Gilchrist, Susan C., primary, and Vilar, Eduardo, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure S2 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome

Author

Deng, Nan, primary, Reyes-Uribe, Laura, primary, Fahrmann, Johannes F., primary, Thoman, Whittney S., primary, Munsell, Mark F., primary, Dennison, Jennifer B., primary, Murage, Eunice, primary, Wu, Ranran, primary, Hawk, Ernest T., primary, Thirumurthi, Selvi, primary, Lynch, Patrick M., primary, Dieli-Conwright, Christina M., primary, Lazar, Alexander J., primary, Jindal, Sonali, primary, Chu, Khoi, primary, Chelvanambi, Manoj, primary, Basen-Engquist, Karen, primary, Li, Yisheng, primary, Wargo, Jennifer A., primary, McAllister, Florencia, primary, Allison, James P., primary, Sharma, Padmanee, primary, Sinha, Krishna M., primary, Hanash, Samir, primary, Gilchrist, Susan C., primary, and Vilar, Eduardo, primary

Published
2023
Full Text
View/download PDF

20. Data from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome

Author

Deng, Nan, primary, Reyes-Uribe, Laura, primary, Fahrmann, Johannes F., primary, Thoman, Whittney S., primary, Munsell, Mark F., primary, Dennison, Jennifer B., primary, Murage, Eunice, primary, Wu, Ranran, primary, Hawk, Ernest T., primary, Thirumurthi, Selvi, primary, Lynch, Patrick M., primary, Dieli-Conwright, Christina M., primary, Lazar, Alexander J., primary, Jindal, Sonali, primary, Chu, Khoi, primary, Chelvanambi, Manoj, primary, Basen-Engquist, Karen, primary, Li, Yisheng, primary, Wargo, Jennifer A., primary, McAllister, Florencia, primary, Allison, James P., primary, Sharma, Padmanee, primary, Sinha, Krishna M., primary, Hanash, Samir, primary, Gilchrist, Susan C., primary, and Vilar, Eduardo, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Materials and Methods 1 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome

Author

Deng, Nan, primary, Reyes-Uribe, Laura, primary, Fahrmann, Johannes F., primary, Thoman, Whittney S., primary, Munsell, Mark F., primary, Dennison, Jennifer B., primary, Murage, Eunice, primary, Wu, Ranran, primary, Hawk, Ernest T., primary, Thirumurthi, Selvi, primary, Lynch, Patrick M., primary, Dieli-Conwright, Christina M., primary, Lazar, Alexander J., primary, Jindal, Sonali, primary, Chu, Khoi, primary, Chelvanambi, Manoj, primary, Basen-Engquist, Karen, primary, Li, Yisheng, primary, Wargo, Jennifer A., primary, McAllister, Florencia, primary, Allison, James P., primary, Sharma, Padmanee, primary, Sinha, Krishna M., primary, Hanash, Samir, primary, Gilchrist, Susan C., primary, and Vilar, Eduardo, primary

Published
2023
Full Text
View/download PDF

24. Molecular cancer prevention: Current status and future directions

Author

Maresso, Karen Colbert, Tsai, Kenneth Y, Brown, Powel H, Szabo, Eva, Lippman, Scott, and Hawk, Ernest T

Subjects
Breast Cancer, Prevention, Cancer, Prevention of disease and conditions, and promotion of well-being, 3.3 Nutrition and chemoprevention, Good Health and Well Being, Humans, Molecular Targeted Therapy, Neoplasms, Practice Guidelines as Topic, molecular prevention, chemoprevention, prevention, randomized controlled trial, Clinical Sciences, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

The heterogeneity and complexity of advanced cancers strongly support the rationale for an enhanced focus on molecular prevention as a priority strategy to reduce the burden of cancer. Molecular prevention encompasses traditional chemopreventive agents as well as vaccinations and therapeutic approaches to cancer-predisposing conditions. Despite challenges to the field, we now have refined insights into cancer etiology and early pathogenesis; successful risk assessment and new risk models; agents with broad preventive efficacy (eg, aspirin) in common chronic diseases, including cancer; and a successful track record of more than 10 agents approved by the US Food and Drug Administration for the treatment of precancerous lesions or cancer risk reduction. The development of molecular preventive agents does not differ significantly from the development of therapies for advanced cancers, yet it has unique challenges and special considerations given that it most often involves healthy or asymptomatic individuals. Agents, biomarkers, cohorts, overall design, and endpoints are key determinants of molecular preventive trials, as with therapeutic trials, although distinctions exist for each within the preventive setting. Progress in the development and evolution of molecular preventive agents has been steadier in some organ systems, such as breast and skin, than in others. In order for molecular prevention to be fully realized as an effective strategy, several challenges to the field must be addressed. Here, the authors provide a brief overview of the context for and special considerations of molecular prevention along with a discussion of the results from major randomized controlled trials.

Published
2015

25. Five National Cancer Institute–designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials

Author

Hawk, Ernest T, Habermann, Elizabeth B, Ford, Jean G, Wenzel, Jennifer A, Brahmer, Julie R, Chen, Moon S, Jones, Lovell A, Hurd, Thelma C, Rogers, Lisa M, Nguyen, Lynne H, Ahluwalia, Jasjit S, Fouad, Mona, and Vickers, Selwyn M

Subjects
Health Services and Systems, Biomedical and Clinical Sciences, Health Sciences, Prevention, Cancer, Clinical Research, Behavioral and Social Science, Basic Behavioral and Social Science, Good Health and Well Being, Catchment Area, Health, Clinical Trials as Topic, Female, Health Services Accessibility, Healthcare Disparities, Humans, Minority Groups, National Cancer Institute (U.S.), Neoplasms, Patient Selection, Poverty, Racial Groups, Research Design, SEER Program, Socioeconomic Factors, United States, Vulnerable Populations, Women, minority enrollment, clinical trials, health disparities, Cancer Center Support Grant, quantitative data, catchment area, data definitions, Continental Population Groups, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundTo ensure that National Institutes of Health-funded research is relevant to the population's needs, specific emphasis on proportional representation of minority/sex groups into National Cancer Institute (NCI) cancer centers' clinical research programs is reported to the NCI.MethodsEMPaCT investigators at 5 regionally diverse comprehensive cancer centers compared data reported to the NCI for their most recent Cancer Center Support Grant competitive renewal to assess and compare the centers' catchment area designations, data definitions, data elements, collection processes, reporting, and performance regarding proportional representation of race/ethnicity and sex subsets.ResultsCancer centers' catchment area definitions differed widely in terms of their cancer patient versus general population specificity, levels of specificity, and geographic coverage. Racial/ethnic categories were similar, yet were defined differently, across institutions. Patients' socioeconomic status and insurance status were inconsistently captured across the 5 centers.ConclusionsCatchment area definitions and the collection of patient-level demographic factors varied widely across the 5 comprehensive cancer centers. This challenged the assessment of success by cancer centers in accruing representative populations into the cancer research enterprise. Accrual of minorities was less than desired for at least 1 racial/ethnic subcategory at 4 of the 5 centers. Institutions should clearly and consistently declare their primary catchment area and the rationale and should report how race/ethnicity and sex are defined, determined, collected, and reported. More standardized, frequent, consistent collection, reporting, and review of these data are recommended, as is a commitment to collecting socioeconomic data, given that socioeconomic status is a primary driver of cancer disparities in the United States.

Published
2014

26. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-associated Immunity in Lynch Syndrome

Author

Deng, Nan, primary, Reyes-Uribe, Laura, additional, Fahrmann, Johannes F., additional, Thoman, Whittney S., additional, Munsell, Mark F., additional, Dennison, Jennifer B., additional, Murage, Eunice, additional, Wu, Ranran, additional, Hawk, Ernest T., additional, Thirumurthi, Selvi, additional, Lynch, Patrick M., additional, Dieli-Conwright, Christina M., additional, Lazar, Alexander J., additional, Jindal, Sonali, additional, Chu, Khoi, additional, Chelvanambi, Manoj, additional, Basen-Engquist, Karen, additional, Li, Yisheng, additional, Wargo, Jennifer A., additional, McAllister, Florencia, additional, Allison, James P., additional, Sharma, Padmanee, additional, Sinha, Krishna M., additional, Hanash, Samir, additional, Gilchrist, Susan C., additional, and Vilar, Eduardo, additional

Published
2023
Full Text
View/download PDF

27. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma

Author

Hatia, Rikita I., primary, Eluri, Madhulika, additional, Hawk, Ernest T., additional, Shalaby, Akram, additional, Karatas, Elif, additional, Shalaby, Ahmed, additional, Abdelhakeem, Ahmed, additional, Abdel-Wahab, Reham, additional, Chang, Ping, additional, Rashid, Asif, additional, Jalal, Prasun K., additional, Amos, Christopher I., additional, Han, Younghun, additional, Armaghany, Tannaz, additional, Shroff, Rachna T., additional, Li, Donghui, additional, Javle, Milind, additional, and Hassan, Manal M., additional

Published
2023
Full Text
View/download PDF

28. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

29. Screening and Early Detection

Author

Bevers, Therese, primary, El-Serag, Hashem, additional, Hanash, Samir, additional, Thrift, Aaron P., additional, Tsai, Kenneth, additional, Maresso, Karen Colbert, additional, and Hawk, Ernest, additional

Published
2020
Full Text
View/download PDF

30. Lifestyle and Cancer Prevention

Author

Basen-Engquist, Karen, primary, Brown, Powel, additional, Coletta, Adriana M., additional, Savage, Michelle, additional, Maresso, Karen Colbert, additional, and Hawk, Ernest, additional

Published
2020
Full Text
View/download PDF

32. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma

Author

Hassan, Manal M., Botrus, Gehan, Abdel-Wahab, Reham, Wolff, Robert A., Li, Donghui, Tweardy, David, Phan, Alexandria T., Hawk, Ernest, Javle, Milind, Lee, Ju-Seog, Torres, Harrys A., Rashid, Asif, Lenzi, Renato, Hassabo, Hesham M., Abaza, Yasmin, Shalaby, Ahmed S., Lacin, Sahin, Morris, Jeffrey, Patt, Yehuda Z., Amos, Christopher I., Khaderi, Saira A., Goss, John A., Jalal, Prasun K., and Kaseb, Ahmed O.

Published
2017
Full Text
View/download PDF

33. Creating and Activating an Implementation Community to Drive HPV Vaccine Uptake in Texas: The Role of an NCI-Designated Cancer Center

Author

Bello, Rosalind S., primary, Walsh, Michael T., additional, Harper, Blake, additional, Amos, Charles E., additional, Oestman, Katherine, additional, Nutt, Stephanie, additional, Galindez, Marcita, additional, Block, Kaitlyn, additional, Rechis, Ruth, additional, Bednar, Erica M., additional, Tektiridis, Jennifer, additional, Foxhall, Lewis, additional, Moreno, Mark, additional, Shete, Sanjay, additional, and Hawk, Ernest, additional

Published
2023
Full Text
View/download PDF

34. Perspective on this Article from Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Author

Bertagnolli, Monica M., primary, Eagle, Craig J., primary, Zauber, Ann G., primary, Redston, Mark, primary, Breazna, Aurora, primary, Kim, KyungMann, primary, Tang, Jie, primary, Rosenstein, Rebecca B., primary, Umar, Asad, primary, Bagheri, Donya, primary, Collins, Neal T., primary, Burn, John, primary, Chung, Daniel C., primary, Dewar, Thomas, primary, Foley, T. Raymond, primary, Hoffman, Neville, primary, Macrae, Finlay, primary, Pruitt, Ronald E., primary, Saltzman, John R., primary, Salzberg, Bruce, primary, Sylwestrowicz, Thomas, primary, and Hawk, Ernest T., primary

Published
2023
Full Text
View/download PDF

35. Data from Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial

Author

Cho, Nancy L., primary, Redston, Mark, primary, Zauber, Ann G., primary, Carothers, Adelaide M., primary, Hornick, Jason, primary, Wilton, Andrew, primary, Sontag, Stephen, primary, Nishioka, Norman, primary, Giardiello, Francis M., primary, Saltzman, John R., primary, Gostout, Chris, primary, Eagle, Craig J., primary, Hawk, Ernest T., primary, and Bertagnolli, Monica M., primary

Published
2023
Full Text
View/download PDF

36. Perspective from Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial

Author

Cho, Nancy L., primary, Redston, Mark, primary, Zauber, Ann G., primary, Carothers, Adelaide M., primary, Hornick, Jason, primary, Wilton, Andrew, primary, Sontag, Stephen, primary, Nishioka, Norman, primary, Giardiello, Francis M., primary, Saltzman, John R., primary, Gostout, Chris, primary, Eagle, Craig J., primary, Hawk, Ernest T., primary, and Bertagnolli, Monica M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure from Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis

Author

Gu, Jian, primary, Ajani, Jaffer A., primary, Hawk, Ernest T., primary, Ye, Yuanqing, primary, Lee, Jeffrey H., primary, Bhutani, Manoop S., primary, Hofstetter, Wayne L., primary, Swisher, Stephen G., primary, Wang, Kenneth K., primary, and Wu, Xifeng, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Information from Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Author

Bertagnolli, Monica M., primary, Eagle, Craig J., primary, Zauber, Ann G., primary, Redston, Mark, primary, Breazna, Aurora, primary, Kim, KyungMann, primary, Tang, Jie, primary, Rosenstein, Rebecca B., primary, Umar, Asad, primary, Bagheri, Donya, primary, Collins, Neal T., primary, Burn, John, primary, Chung, Daniel C., primary, Dewar, Thomas, primary, Foley, T. Raymond, primary, Hoffman, Neville, primary, Macrae, Finlay, primary, Pruitt, Ronald E., primary, Saltzman, John R., primary, Salzberg, Bruce, primary, Sylwestrowicz, Thomas, primary, and Hawk, Ernest T., primary

Published
2023
Full Text
View/download PDF

43. Data from Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Author

Bertagnolli, Monica M., primary, Eagle, Craig J., primary, Zauber, Ann G., primary, Redston, Mark, primary, Breazna, Aurora, primary, Kim, KyungMann, primary, Tang, Jie, primary, Rosenstein, Rebecca B., primary, Umar, Asad, primary, Bagheri, Donya, primary, Collins, Neal T., primary, Burn, John, primary, Chung, Daniel C., primary, Dewar, Thomas, primary, Foley, T. Raymond, primary, Hoffman, Neville, primary, Macrae, Finlay, primary, Pruitt, Ronald E., primary, Saltzman, John R., primary, Salzberg, Bruce, primary, Sylwestrowicz, Thomas, primary, and Hawk, Ernest T., primary

Published
2023
Full Text
View/download PDF

46. Data from Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

Author

Meyskens, Frank L., primary, McLaren, Christine E., primary, Pelot, Daniel, primary, Fujikawa-Brooks, Sharon, primary, Carpenter, Philip M., primary, Hawk, Ernest, primary, Kelloff, Gary, primary, Lawson, Michael J., primary, Kidao, Jayashri, primary, McCracken, John, primary, Albers, C. Gregory, primary, Ahnen, Dennis J., primary, Turgeon, D. Kim, primary, Goldschmid, Steven, primary, Lance, Peter, primary, Hagedorn, Curt H., primary, Gillen, Daniel L., primary, and Gerner, Eugene W., primary

Published
2023
Full Text
View/download PDF

47. Perspective from Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

Author

Meyskens, Frank L., primary, McLaren, Christine E., primary, Pelot, Daniel, primary, Fujikawa-Brooks, Sharon, primary, Carpenter, Philip M., primary, Hawk, Ernest, primary, Kelloff, Gary, primary, Lawson, Michael J., primary, Kidao, Jayashri, primary, McCracken, John, primary, Albers, C. Gregory, primary, Ahnen, Dennis J., primary, Turgeon, D. Kim, primary, Goldschmid, Steven, primary, Lance, Peter, primary, Hagedorn, Curt H., primary, Gillen, Daniel L., primary, and Gerner, Eugene W., primary

Published
2023
Full Text
View/download PDF

48. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Author

Meyskens, Frank L, Jr, McLaren, Christine E, Pelot, Daniel, Fujikawa-Brooks, Sharon, Carpenter, Philip M, Hawk, Ernest, Kelloff, Gary, Lawson, Michael J, Kidao, Jayashri, McCracken, John, Albers, C Gregory, Ahnen, Dennis J, Turgeon, D Kim, Goldschmid, Steven, Lance, Peter, Hagedorn, Curt H, Gillen, Daniel L, and Gerner, Eugene W

Subjects
Adenoma: diagnosis, prevention & control, Adult, Aged, Algorithms, Antineoplastic Combined Chemotherapy Protocols: adverse effects, therapeutic use, Colonoscopy, Colorectal Neoplasms: diagnosis, prevention & control, Double-Blind Method, Eflornithine: administration & dosage, adverse effects, Female, Humans, Male, Middle Aged, Placebos, Sulindac: administration & dosage, adverse effects, Treatment Outcome, antineoplastic agent, eflornithine, placebo, sulindac, adenoma, adult, aged, algorithm, article, clinical trial, colonoscopy, colorectal tumor, controlled clinical trial, controlled study, double blind procedure, female, human, male, middle aged, randomized controlled trial, treatment outcome, Adenoma, Adult, Aged, Algorithms, Antineoplastic Combined Chemotherapy Protocols, Colonoscopy, Colorectal Neoplasms, Double-Blind Method, Eflornithine, Female, Humans, Male, Middle Aged, Placebos, Sulindac, Treatment Outcome
Abstract

Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas. Three hundred seventy-five patients with history of resected (> or =3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline and clinical site. Follow-up colonoscopy was done 3 years after randomization or off-study. Colorectal adenoma recurrence was compared among the groups with log-binomial regression. Comparing the outcome in patients receiving placebos to those receiving active intervention, (a) the recurrence of one or more adenomas was 41.1% and 12.3% (risk ratio, 0.30; 95% confidence interval, 0.18-0.49; P < 0.001); (b) 8.5% had one or more advanced adenomas, compared with 0.7% of patients (risk ratio, 0.085; 95% confidence interval, 0.011-0.65; P < 0.001); and (c) 17 (13.2%) patients had multiple adenomas (>1) at the final colonoscopy, compared with 1 (0.7%; risk ratio, 0.055; 0.0074-0.41; P < 0.001). Serious adverse events (grade > or =3) occurred in 8.2% of patients in the placebo group, compared with 11% in the active intervention group (P = 0.35). There was no significant difference in the proportion of patients reporting hearing changes from baseline. Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.

Published
2008

50. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

Author

Kelloff, Gary J, Lippman, Scott M, Dannenberg, Andrew J, Sigman, Caroline C, Pearce, Homer L, Reid, Brian J, Szabo, Eva, Jordan, V Craig, Spitz, Margaret R, Mills, Gordon B, Papadimitrakopoulou, Vali A, Lotan, Reuben, Aggarwal, Bharat B, Bresalier, Robert S, Kim, Jeri, Arun, Banu, Lu, Karen H, Thomas, Melanie E, Rhodes, Helen E, Brewer, Molly A, Follen, Michele, Shin, Dong M, Parnes, Howard L, Siegfried, Jill M, Evans, Alison A, Blot, William J, Chow, Wong-Ho, Blount, Patricia L, Maley, Carlo C, Wang, Kenneth K, Lam, Stephen, Lee, J Jack, Dubinett, Steven M, Engstrom, Paul F, Meyskens, Frank L, O'Shaughnessy, Joyce, Hawk, Ernest T, Levin, Bernard, Nelson, William G, Hong, Waun Ki, and Prevention, for the AACR Task Force on Cancer

Subjects
Clinical Research, Cancer, Prevention, Clinical Trials and Supportive Activities, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Biomarkers, Tumor, Breast Neoplasms, Chemoprevention, Colorectal Neoplasms, Disease Progression, Female, Humans, Infections, Inflammation, Male, Monitoring, Physiologic, Neoplasms, Glandular and Epithelial, Signal Transduction, AACR Task Force on Cancer Prevention, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results